A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections.

NPR's Pien Huang speaks with pediatrician Alexandra Cvijanovich and Professor Jason L. Schwartz about trying to shore up ...

Eli Lilly (NYSE: LLY) led the way in pharma M&A during June. The US pharma major announced two major deals in the month, both ...